Integral Health Asset Management LLC Takes Position in Repligen Co. (NASDAQ:RGEN)

Integral Health Asset Management LLC acquired a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,000 shares of the biotechnology company's stock, valued at approximately $5,758,000. Integral Health Asset Management LLC owned approximately 0.07% of Repligen as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in RGEN. Signaturefd LLC lifted its stake in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen in the fourth quarter valued at about $29,000. Itau Unibanco Holding S.A. bought a new position in shares of Repligen in the fourth quarter valued at about $40,000. UMB Bank n.a. raised its position in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares during the period. Finally, Global Retirement Partners LLC raised its position in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

NASDAQ:RGEN traded up $3.24 during mid-day trading on Friday, reaching $126.50. 1,245,890 shares of the company's stock were exchanged, compared to its average volume of 735,546. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a one year low of $102.97 and a one year high of $182.52. The firm has a market capitalization of $7.11 billion, a PE ratio of -248.04, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. The business's fifty day simple moving average is $132.74 and its two-hundred day simple moving average is $145.12.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. During the same period last year, the firm earned $0.28 EPS. The business's quarterly revenue was up 10.4% compared to the same quarter last year. Analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RGEN shares. Royal Bank of Canada dropped their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective on the stock. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research report on Tuesday, April 29th. Finally, Canaccord Genuity Group dropped their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.